Skip to main content

Table 4 Characteristics of the 20 pairs of chronically HVC infected patients and their exposed uninfected partners

From: Hepatitis C virus-specific cellular immune responses in individuals with no evidence of infection

I.D*

Sex

HCV infection**

Proliferation***

Elispot****

   

Viral load

Genotype

Duration

Mode

Core

NS3

CEF

Core

NS3

CEF

CI

CIC 02

F

354 000

1b

22

Blood T

(-)

(-)

143(T8)

10

ND

ND

EUI

CIC 01

M

-

-

-

-

(-), bgd

(-), bdg

10(T8), bgd

(-)

(-)

4

CI

CIC 10

F

20 000

4

ND

Unknown

(-)

(-)

18(T8)

(-)

(-)

6

EUI

CIC 11

M

-

-

-

-

ND

ND

ND

(-)

bgd

bgd

CI

CIC 12

F

210 000

4c/b

15

Surgery

bgd

bgd

bgd

(-)

ND

ND

EUI

CIC 13

M

-

-

-

-

(-), bgd

(-), bgd

5(T8), bgd

(-)

(-)

16

CI

CIC 14

F

1 850 000

1a

24

IVDU

(-)

(-)

11(T8)

(-)

ND

ND

EUI

CIC 15

M

-

-

  

ND

ND

ND

(-)

(-)

13

CI

CIC 18

F

380 000

3

24

IVDU

(-)

76 (T8)

(-)

21

295

(-)

EUI

CIC 19

M

-

-

-

-

(-)

(-)

(-)

(-)

(-)

(-)

CI

CIC 25

M

1 300 000

1b

23

tattooing

(-)

ND

ND

4

ND

ND

EUI

CIC 24

F

-

-

-

-

(-)

(-)

83(T8)

12

ND

ND

CI

CIC 26

M

215 000

1b

16

Blood T

(-)

(-)

11(T8)

(-)

ND

ND

EUI

CIC 27

F

-

-

-

-

(-), bgd

(-), bgd

(-), bgd

(-)

ND

ND

CI

CIC 29

F

30 000

ND

ND

Unknown

bgd

bgd

bgd

(-)

(-)

(-)

EUI

CIC 28

M

-

-

-

-

(-)

(-)

37(T8)

7

bgd

bgd

CI

CIC 31

M

200 000

1b

37

Blood T

ND

ND

ND

8

ND

ND

EUI

CIC 30

F

-

-

-

-

(-)

(-)

9(T8)

55

(-)

45

CI

CIC 32

M

1 425 000

1b

ND

Unknown

(-)

(-)

(-)

10

ND

ND

EUI

CIC 33

F

-

-

-

-

(-)

(-)

(-)

(-)

ND

ND

CI

CIC 34

M

100 000

1b

16

Blood T

14(T8)

(-)

(-)

(-)

ND

ND

EUI

CIC 35

F

-

-

-

-

(-)

(-)

(-)

(-)

(-)

89

CI

CIC 36

F

35 000

3a

ND

Unknown

(-)

(-)

29(T8)

(-)

ND

ND

EUI

CIC 37

M

-

-

-

-

(-)

(-)

(-)

12

(-)

72

CI

CIC 38

F

260 000

1a

43

Blood T

7(T4)

4(T4)

433(T8)

(-)

ND

ND

EUI

CIC 39

M

-

-

-

-

(-)

(-)

(-)

(-)

ND

ND

CI

CIC 40

M

332 000

1a

16

Blood T

(-)

(-)

10(T8)

19

8

100

EUI

CIC 41

F

-

-

-

-

(-)

(-)

(-)

10

ND

ND

CI

CIC 42

F

140 000

1b

20

Blood T

(-)

(-)

(-)

(-)

(-)

(-)

EUI

CIC 43

M

-

-

-

-

(-)

(-)

(-)

(-)

7

(-)

CI

CIC 44

F

82 000

1b

22

Blood T

ND

ND

ND

(-)

ND

ND

EUI

CIC 45

M

-

-

-

-

(-)

(-)

(-)

11

(-)

(-)

CI

CIC 46

M

2 200 000

1b

25

Blood T

6(T4)

(-)

434(T8)

10

(-)

2070

EUI

CIC 47

F

-

-

-

-

(-)

(-)

(-)

(-)

ND

ND

CI

CIC 51

M

180 000

2a/c

22

Blood T

ND

ND

ND

(-)

ND

ND

EUI

CIC 52

F

-

-

-

-

ND

ND

ND

(-)

ND

ND

CI

CIC 60

M

720 000

1a

18

IVDU

(-)

(-)

7(T8)

(-)

ND

ND

EUI

CIC 61

F

-

-

-

-

(-), bgd

(-), bgd

(-), bgd

(-)

ND

ND

CI

CIC 64

M

1 080 000

1b

ND

Unknown

(-)

(-)

(-)

81

ND

ND

EUI

CIC 65

F

-

-

-

-

(-)

(-)

(-)

(-)

ND

ND

  1. *: Chronically HCV-infected subjects (CI); Exposed uninfected partners of chronically infected individuals (EUI).
  2. **: Viral load expressed as LU per mL; Duration of HCV infection in years; Blood T blood transfusion, IVDU intravenous drug users.
  3. ** (-) = absence, or xx = presence of antigen-specific proliferation. The number xx stands for specific to control antigen ration, and (T4) or (T8) for the nature of the proliferating lymphocyte population.
  4. ***(-) = no antigen specific ELISPOT; xx = presence of antigen specific ELISPOT. The number stands for specific antigen to control ratio.
  5. Abbreviations: bgd background proliferation without antigen. ND Not determine.
  6. The CEF panel of EBV, CMV and Flu peptides is described in ref 12.